Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 725 of 1048 entries
View as:

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT07019363 Org: User:
Start: 06/15/25 End: 04/15/33 Due: 04/15/34

NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05131763 Org: User:
Start: 03/01/21 End: 12/01/23 Due: 12/01/24

DEBIRI Combined With Chemotherapy and Bevacizumab in the Treatment of Unresectable Colorectal Cancer Liver Metastases

Phase: N/A Priority: Normal
NCT ID: NCT06177288 Org: User:
Start: 01/01/24 End: 05/01/25 Due: 05/01/26

Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04995120 Org: User:
Start: 04/07/21 End: 12/31/25 Due: 12/31/26

Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06039631 Org: User:
Start: 08/22/23 End: 09/01/29 Due: 09/01/30

Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET

Phase: N/A Priority: Normal
NCT ID: NCT04992156 Org: User:
Start: 03/15/17 End: 04/15/22 Due: 04/15/23

Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT01192230 Org: User:
Start: 06/30/09 End: - Due: -

Impact of a Mock-up Fact-checking Extension on HPV Vaccine Misinformation: A Survey Experiment

Phase: N/A Priority: Normal
NCT ID: NCT06405048 Org: User:
Start: 04/28/24 End: 06/30/24 Due: 06/30/25

ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT05018702 Org: User:
Start: 07/14/21 End: 06/30/23 Due: 06/30/24

Short-term Health Benefits of Using Fresh Air Filtration System in Classroom

Phase: N/A Priority: Normal
NCT ID: NCT03788330 Org: User:
Start: 12/07/18 End: 01/22/19 Due: 01/22/20

Positive ER Expression Assessed by 18F-FES PET/CT in the MBC with ER-negative Primary Tumor

Phase: N/A Priority: Normal
NCT ID: NCT06344767 Org: User:
Start: 09/01/23 End: 05/05/24 Due: 05/05/25

Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles

Phase: N/A Priority: Normal
NCT ID: NCT00868816 Org: User:
Start: 01/31/05 End: 12/31/07 Due: 12/31/08

Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06250972 Org: User:
Start: 05/15/24 End: 05/01/28 Due: 05/01/29

TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04297280 Org: User:
Start: 04/29/20 End: 02/25/25 Due: 02/25/26

Study of Urinary Angiotensinogen as a Marker to Warn the Deterioration of Renal Function in CKD Patients Early.

Phase: N/A Priority: Normal
NCT ID: NCT01118494 Org: User:
Start: 09/30/09 End: 06/30/11 Due: 06/30/12

Health Benefits of Air Purifiers in Primary School Students

Phase: N/A Priority: Normal
NCT ID: NCT05016271 Org: User:
Start: 09/22/21 End: 06/30/26 Due: 06/30/27

TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04954781 Org: User:
Start: 07/14/21 End: 07/15/25 Due: 07/15/26

A Study of Lymph Node Metastatic Pattern Based Incorporating Tumor Location, GGO Components and Size for Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06161935 Org: User:
Start: 04/30/08 End: 07/31/23 Due: 07/31/24

Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT04164368 Org: User:
Start: 10/22/19 End: 08/30/23 Due: 08/30/24

A Phase II Trial of Exploring the Predictive Factors of TX and XELOX Regimen in the First Line Treatment of MGC

Phase: N/A Priority: Normal
NCT ID: NCT01963702 Org: User:
Start: 08/31/12 End: 12/31/14 Due: 12/31/15

Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping

Phase: N/A Priority: Normal
NCT ID: NCT06561022 Org: User:
Start: 08/21/24 End: 06/30/26 Due: 06/30/27

Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT04472806 Org: User:
Start: 06/20/20 End: 06/20/23 Due: 06/20/24

Lung Atelectasis Improvement Through Positive End Expiratory Pressure During Anesthetic Induction

Phase: N/A Priority: Normal
NCT ID: NCT06900426 Org: User:
Start: 03/28/25 End: 04/28/25 Due: 04/28/26

Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03274011 Org: User:
Start: 07/01/17 End: 06/26/19 Due: 06/26/20

A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06158919 Org: User:
Start: 11/20/23 End: 11/20/26 Due: 11/20/27